NanoViricides Reports Progress on Broad-Spectrum Antiviral NV-387 Amid Public Health Concerns

NanoViricides, Inc. has filed its Form 10-Q for the quarter ended September 30, 2025, detailing substantial progress on its lead drug candidate NV-387, a first-in-class broad-spectrum antiviral designed to resist viral escape by mimicking conserved sulfated proteoglycan receptors used by more than 90% of viruses. The company's quarterly report emphasizes that NV-387's unique mechanism may address major unmet needs across multiple viral diseases, including Influenza strains prone to rapid resistance, RSV, Measles, MPox, and gaps in existing Smallpox countermeasures. This development comes at a critical time when public health systems face challenges from the dominant A/H3N2 clade K variant and a mismatched seasonal vaccine with historically low efficacy, underscoring the urgent need for antiviral solutions that maintain effectiveness as viruses evolve.

The company's approach represents a potential paradigm shift in antiviral therapy, moving away from virus-specific treatments toward broader-spectrum solutions that could be effective against multiple viral threats simultaneously. NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy, with its novel nanoviricide class of drug candidates based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections, though the agreement excludes cancer and similar diseases that may have viral origin but require different treatment approaches.

NanoViricides' business model involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. The company holds broad, exclusive, sub-licensable field licenses to drugs developed in several licensed fields from TheraCour. The platform technology and programs are based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. Beyond NV-387, NanoViricides is developing drugs against numerous viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.

The company maintains a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of multiple human viral diseases. Additional information about the company's developments is available in their newsroom at https://ibn.fm/NNVC. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, positioning it as a potential solution for treating RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Another advanced drug candidate in development is NV-HHV-1 for the treatment of Shingles.

However, the company notes that it cannot project an exact date for filing an Investigational New Drug application for any of its drugs due to dependence on external collaborators and consultants. As with all pharmaceutical development, the path to drug approval remains lengthy and requires substantial capital investment. The company acknowledges the inherent risks in drug development, stating that there can be no assurance at this time that any of its pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development, or that successful laboratory results will lead to successful clinical trials or commercial products.